PUNE, India, May 9, 2016 /PRNewswire/ --
RnRMarketResearch.com adds "Glaucoma - Pipeline Review, H1 2016" to its store providing comparative analysis of Glaucoma pipeline therapeutics at various stages, assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects.
Complete report on H1 2016 pipeline review of Glaucoma with 100 market data tables and 17 figures, spread across 331 pages is available at http://www.rnrmarketresearch.com/glaucoma-pipeline-review-h1-2016-market-report.html .
The report also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Glaucoma Pipeline Review, H1 2016 report include AC Immune SA, Acadia Pharmaceuticals Inc., Advanced Refractive Technologies, Inc., Aerie Pharmaceuticals, Inc., Allergan Plc, Altacor Limited, Amakem NV, Amarantus Bioscience Holdings, Inc., Astellas Pharma Inc., AUS Bio Limited, Bausch & Lomb Incorporated, BioAxone BioSciences, Inc., Bionure Farma, S.L., Caladrius Biosciences, Inc., Can-Fite BioPharma Ltd., Coronis Partners Ltd., D. Western Therapeutics Institute, Inc., Dompe Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., Gene Signal International SA, Gilead Sciences, Inc., Glaukos Corporation, GliaCure Inc., Handok Inc., Icon Bioscience, Inc., ID Pharma Co., Ltd., InMed Pharmaceuticals Inc., Inotek Pharmaceuticals Corporation, InSite Vision Incorporated, Isarna Therapeutics GmbH, Kadmon Corporation, LLC, Kala Pharmaceuticals, Inc., Kowa Company, Ltd., Kukje Pharmaceutical Industry Co., Ltd., Lee's Pharmaceutical Holdings Limited, Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., Merz Pharma GmbH & Co. KgaA, Nemus Bioscience, Inc., Neurotech Pharmaceuticals, Inc., NicOx S.A., NoNO, Inc., Novaliq GmbH, Ocular Therapeutix, Inc., Oculis ehf, Ohr Pharmaceutical Inc., Ono Pharmaceutical Co., Ltd., Otsuka Holdings Co., Ltd., Oxford BioMedica Plc, pSivida Corp., Quark Pharmaceuticals, Inc., Quethera Limited, Regeneron Pharmaceuticals, , nc., Sanofi, Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., Shire Plc, SK Biopharmaceuticals Co., Ltd., Sun Pharma Advanced Research Company Ltd., Sylentis S.A.U., UAB Profarma, ViSci Ltd. and vTv Therapeutics LLC.
Drug profiles discussed in this research report includes (carteolol hydrochloride + latanoprost), (dorzolamide hydrochloride + latanoprost), (latanoprost + netarsudil mesylate), (latanoprost + trabodenoson), (tafluprost + timolol maleate), AC-262271, ACI-260, ACN-1052, aflibercept, aganirsen, ALT-022, ALY-1337, AMA-0076, AMRS-001, Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy, Antisense Oligonucleotides to Inhibit P16INK4a for Primary Open-Angle Glaucoma (POAG), APH-1104, BA-1049, BA-240, bamosiran, bimatoprost, bimatoprost, bimatoprost SR, Biologic for Glaucoma, N-201, brimonidine tartrate, CTI-085, DE-117, decorin, Drug for Glaucoma, Drug for Glaucoma, Drugs for Steroid Induced Glaucoma, Drugs to Target Bestrophin-2 for Glaucoma, EG-30, ethosuximide, GB-201, GB-202, GB-203, GB-204, GC-021109, Gene Therapy for Glaucoma, Gene Therapy for Glaucoma and Retinitis Pigmentosa, Gene Therapy for Ocular Diseases, Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension, Glaucoma-GT, GS-607601, H-1129, HL-3501, HPP-851, ISTH-0036, KJ-13003, KJ-14002, KL-00199, KR-12, latanoprost, latanoprost SR, latanoprostene bunod, levobetaxolol hydrochloride, lomerizine, LX-7101, MD-920G, Monoclonal Antibodies to Antagonize Cadherin-5 for Glaucoma, MRZ-99030, NB-1111, NCX-1021, NCX-250, NCX-470, NCX-667, netarsudil mesylate, neurovitas, Nov-04, NT-501, OC-201, OC-410, ONO-9054, OPA-6566, PBF-677, PF-08, piclidenoson, QPI-1007, R-801, R-807, Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology, RG-4929, ripasudil, RO-5093151, SAR-366234, SHP-639, SKL-G, Small Molecule for Glaucoma, Small Molecule to Agonize 5HT2 for Glaucoma, Small Molecule to Inhibit Rho Kinase for , laucoma Sm all Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy, Small Molecules for CNS Disorders and Ophthalmology, Small Molecules for Glaucoma, Small Molecules for Neurological and Ophthalmological Diseases, Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma, Small Molecules to Antagonize TRPV4 for Glaucoma, Small Molecules to Inhibit Dual Leucine Zipper Kinase for Glaucoma and Neurodegenerative Disorders, Small Molecules to Inhibit LIMK1 AND LIMK2 for Cancer and Ophthalmology, SNC-121, SNJ-1656, SNJ-1945, Stem Cell Therapy for Glaucoma, Stem Cell Therapy for Macular Degeneration and Glaucoma, Synthetic Peptide for Glaucoma, TG-46, trabodenoson, travoprost, travoprost SR, travoprost XR, TRV-32R and UM-5050.
Order a copy of Glaucoma - Pipeline Review, H1 2016 market research report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=539814 .
Explore more reports on Ophthalmology therapeutics.
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
SOURCE RnR Market Research